COMPANY

BioMendics

Keywords: epidermolysis bullosa simplex epidermolysis bullosa small molecule epidermolytic hyperkeratosis Wound Healing

Profile checked Oct 10, 2026

Timeline

Sep 11, 2025 Trial start II: A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex source ↗
May 5, 2022 Trial start Phase 1: Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex source ↗
Aug 26, 2019 Trial start Phase 2: Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants source ↗
Jul 16, 2018 Trial start Phase 1: Safety and Efficacy of Topical TolaSure on Skin Punch Biopsies in Healthy Participants source ↗

2027-01 (ESTIMATED) · II · A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex · NCT07027345

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07027345	A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex	II	Recruiting	Sep 11, 2025	2027-01 (estimated)
NCT05062070	Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex	Phase 1	Completed	May 5, 2022	Jun 22, 2023 (actual)
NCT04088357	Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants	Phase 2	Completed	Aug 26, 2019	Apr 22, 2020 (actual)
NCT03620175	Safety and Efficacy of Topical TolaSure on Skin Punch Biopsies in Healthy Participants	Phase 1	Completed	Jul 16, 2018	Dec 12, 2018 (actual)